ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
ClearPoint Neuro Inc

ClearPoint Neuro Inc (CLPT)

7.69
0.52
(7.25%)
Closed July 23 4:00PM
7.69
0.00
( 0.00% )
Pre Market: 4:09AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
7.69
Bid
6.98
Ask
12.30
Volume
-
0.00 Day's Range 0.00
4.05 52 Week Range 7.97
Market Cap
Previous Close
7.69
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
172,386
Shares Outstanding
27,420,327
Dividend Yield
-
PE Ratio
-6.37
Earnings Per Share (EPS)
-0.81
Revenue
23.96M
Net Profit
-22.09M

About ClearPoint Neuro Inc

MRI Interventions Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It has two product platforms: ... MRI Interventions Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It has two product platforms: ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace system, which is under development, to be used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint Neuro Intervention System and The ClearTrace Cardiac Intervention System. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
ClearPoint Neuro Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker CLPT. The last closing price for ClearPoint Neuro was $7.69. Over the last year, ClearPoint Neuro shares have traded in a share price range of $ 4.05 to $ 7.97.

ClearPoint Neuro currently has 27,420,327 shares outstanding. The market capitalization of ClearPoint Neuro is $210.86 million. ClearPoint Neuro has a price to earnings ratio (PE ratio) of -6.37.

CLPT Latest News

ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise...

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial

SOLANA BEACH, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise...

Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons

Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons PR Newswire SAN DIEGO, June 20, 2024 Aspen Neuroscience...

ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System

SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.273.638814016177.427.726.9981427.31743373CS
42.1538.80866425995.547.96865.112155006.56145929CS
122.2641.6206261515.437.96865.111723866.08377166CS
26-0.07-0.902061855677.767.975.1051593966.33026415CS
520.8412.26277372266.857.974.051312176.15387435CS
156-12.37-61.66500498520.0622.84.0516018610.39573371CS
2602.0937.32142857145.631.292.860117762513.10011136CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DRMADermata Therapeutics Inc
$ 4.09
(214.62%)
5.1M
NUZENuZee Inc
$ 1.77
(71.84%)
1.33M
RGCRegencell Bioscience Holdings Ltd
$ 22.10
(47.73%)
302.62k
ALLRAllarity Therapeutics Inc
$ 0.2442
(46.67%)
19.13M
NIVFNewGenIvf Group Ltd
$ 1.13
(29.75%)
1.64M
CONNConns Inc
$ 0.3287
(-35.17%)
78.81k
VSTMVerastem Inc
$ 2.62
(-27.02%)
33.77k
ATPCAgape ATP Corporation
$ 0.172
(-20.00%)
214.99k
SLRXSalarius Pharmaceuticals Inc
$ 2.10
(-19.54%)
41.63k
ALPPAlpine 4 Holdings Inc
$ 0.4859
(-19.00%)
28.51k
ALLRAllarity Therapeutics Inc
$ 0.2461
(47.81%)
19.13M
SLNASelina Hospitality PLC
$ 0.0279
(7.31%)
7.52M
DRMADermata Therapeutics Inc
$ 3.99
(206.92%)
5.1M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 11.67
(-14.82%)
2.12M
NIVFNewGenIvf Group Ltd
$ 1.12
(28.60%)
1.64M

CLPT Discussion

View Posts
Monksdream Monksdream 1 month ago
CLPT under $10
👍️0
Mortimerduke Mortimerduke 6 months ago
Putting their funding to good use!
👍️0
MasterBlastr MasterBlastr 2 years ago
50% haircut last 6 months. Glad I didn't buy when you were hyping this. Looks like you are gone too.
👍️0
VMLG17 VMLG17 3 years ago
Plenty of talk of her on the NWBO board. I'm long on NWBO.
👍️0
oderwacher oderwacher 3 years ago
Doesn't anybody ever talk about Dr. Linda Liau?
👍️0
ronpopeil ronpopeil 3 years ago
I bought in. Very exciting company
👍️0
DayTraderOG DayTraderOG 3 years ago
Oh wow great dip time to scoop some shares on sale
👍️0
DayTraderOG DayTraderOG 3 years ago
Nice news clear point neuro doing big things saving our lives go $CLPT https://www.globenewswire.com/news-release/2021/01/26/2164680/0/en/ClearPoint-Neuro-Inc-Announces-Expansion-of-Pre-Clinical-and-Translational-Development-Team-to-Support-Gene-and-Stem-Cell-Therapy-Partners.html
👍️0
DayTraderOG DayTraderOG 3 years ago
This stock has been great runner daily
👍️0
DayTraderOG DayTraderOG 3 years ago
Everyone missing out on this great stock of the year
👍️0
DayTraderOG DayTraderOG 3 years ago
Good after noon CLPT
👍️0
DayTraderOG DayTraderOG 3 years ago
Going be great in am
👍️0
DayTraderOG DayTraderOG 3 years ago
Yall missed this gem
👍️0
DayTraderOG DayTraderOG 3 years ago
Wow from 7 to 23 if u missed me calling out CLPT where were u
👍️0
DayTraderOG DayTraderOG 4 years ago
Good morning clear point looks like shell be going 30 today by end of week
👍️0
DayTraderOG DayTraderOG 4 years ago
All new highs here anyone missing this ?? losing a lot of free cash
👍️0
MWM MWM 4 years ago
$CLPT very Nice! I have too many plays!!! Very Nice!

👍️0
DayTraderOG DayTraderOG 4 years ago
$CLPT
Keep going up
👍️0
DayTraderOG DayTraderOG 4 years ago
Yall missing out on all this love
👍️0
DayTraderOG DayTraderOG 4 years ago
I like this gem keeps going up like stair case this will be at $50 easy
👍️0
MWM MWM 4 years ago
ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms

https://www.globenewswire.com/news-release/2020/12/29/2151415/0/en/ClearPoint-Neuro-Inc-Announces-Funding-of-Additional-7-5M-of-Existing-Convertible-Note-on-Improved-Terms.html
👍️0
DayTraderOG DayTraderOG 4 years ago
Ive been in since July its been a great ride for me
👍️0
MWM MWM 4 years ago
Nice Find
👍️0
MWM MWM 4 years ago
CLPT one to watch...

Outstanding Shares 16,869,528 11/10/2020

Brain surgery

The Restore-1 trial DSMB did not advise Neurocrine's team to pause or halt the trial back in November, Roberts said. However, it did recommend that the company discontinue its use of the neurosurgical procedure used in the trial at the time, she said. That was presumably a reference to the brain surgery procedure by which NBIb-1817 and another Voyager asset, VY-HTT-01, are designed to be delivered to targeted areas and cells in the brain.

In a previous phase I trial, conducted by the University of California, San Francisco, three patients experienced hemorrhages caused by the surgical procedure for administering VY-AADC, Voyager reported in its most recent quarterly report, on Nov. 9.

In response, in Restore-1, investigators began using Clearpoint Neuro Inc.'s Clearpoint System "to provide accurate placement of the cannula in the putamen and allow for real-time, intra-operative MRI to assist the physician in visualizing the delivery of VY-AADC (NBIb-1817) to the putamen and to avoid specific blood vessels during the duration of the surgical procedure, with the goal of reducing the risk of hemorrhages," Voyager said.

In the same quarterly filing, Voyager said that it might begin using V-TAG, a real-time, intra-operative, MRI-compatible device that it developed with Clearpoint for the procedures.

Even with those changes, the Restore-1 study had been on pause since earlier in the year due to what Roberts called a "major amendment to the study over the course of the summer," one that appears to have included a major streamlining of the trial's primary and secondary outcome measures. Furthermore, screening for the study had been paused as well, particularly in light of the need for trial participants to travel, sometimes across state lines for study-relating brain scans.

Neurocrine's efforts to resolve those issues weren't clear on Wednesday. But Cowen analyst Phil Nadeau remained cautiously optimistic. "The risk to NBIb-1817's further development, as well as the duration of the delay, can't be estimated without understanding the specific issues that the DSMB has identified," he said.

https://www.bioworld.com/articles/501751-fda-puts-parkinsons-trial-on-hold-amid-imaging-abnormalities



👍️0
DayTraderOG DayTraderOG 4 years ago
Wow im glad I know about this gem steadily going up lets have another great say $CLPT
👍️0
DayTraderOG DayTraderOG 4 years ago
This stock will be at 50 dollars one day soon don't get left out this gem
👍️0
DayTraderOG DayTraderOG 4 years ago
Don't sleep on this ticker is the way of future surgery
👍️0
DayTraderOG DayTraderOG 4 years ago
Watching the dips today
👍️0